A Study of Tirzepatide (LY3298176) in Chinese Participants With Type 2 Diabetes

What Was Tested

In this phase 3 trial, researchers set out to test Tirzepatide.

The main purpose of this study is to compare the effect of the addition of tirzepatide or placebo to titrated basal insulin on glycemic control in Chinese participants with type 2 diabetes.

The registry classes the interventions as drug.

Who Took Part

The registry lists 257 actual participants took part.

It was open to people of any sex aged from 18 years with no upper age limit.

Healthy volunteers could join, not only people with the condition.

Examples of who could join: Have type 2 diabetes mellitus (T2DM). Have been treated with insulin glargine (U100) once daily alone, or in combination with metformin with or without SGLT-2i ≥90 days. Have a body mass index (BMI) ≥23 kilograms per meter squared (kg/m²).

The full record lists 4 inclusion and 9 exclusion criteria; among the exclusions: have type 1 diabetes mellitus (t1dm); have a history of chronic or acute pancreatitis; have proliferative diabetic retinopathy or diabetic macular edema or nonproliferative diabetic retinopathy that requires acute treatment.

How the Study Was Run

It was run as a randomized, parallel-group and double-blind study.

Because people in this Tirzepatide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Groups ran in parallel: each of the participants stayed in one arm throughout.

As a double-blind Tirzepatide study, the assignments were hidden from both participants and investigators until the end.

Those kept unaware of assignments: participant and investigator.

It started in 2023-02-05 with completion listed for 2024-07-01.

It ran at 25 sites in China (25).

Its stated primary purpose is treatment.

What Was Measured

It also tracked 15 secondary outcomes, for example Mean Change From Baseline in Body Weight, Mean Change From Baseline in Fasting Serum Glucose and Mean Change From Baseline in Daily Average 7-point Self-monitored Blood Glucose Profiles.

What This Means in Plain Language

Put simply, this is a phase 3, randomized trial of Tirzepatide in 257 people.

The trial is marked completed; results are posted on the registry, and this page does not restate them.

More context: the Tirzepatide compound page, all human trials.